Skip to search formSkip to main contentSkip to account menu

tofacitinib

Known as: 3-((3R,4R)-4-Methyl-3-(Methyl(7H-Pyrrolo(2,3-D)Pyrimidin-4-yl)Amino)Piperidin-1-yl)-3-Oxopropanenitrile, Tasocitinib, Tofacitinibum 
An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds… 
National Institutes of Health

Related topics

Related topics

12 relations
24 HR tofacitinib 11 MG Extended Release Oral TabletJanus Kinase Inhibitors [MoA]Receptor Tyrosine Kinase InhibitionTOFACITINIB CITRATE

Narrower (2)

CP 690,550Xeljanz

Broader (4)

PiperidinesProtein Kinase InhibitorsPyrimidinesPyrroles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia
2017
2017
SAT0439 Integrated safety summary of tofacitinib in psoriatic arthritis clinical studies
Background Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). Objectives To… 
2015
2015
SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Objectives: To report… 
2015
2015
Digestive Disease Week.
Digestive Disease Week (DDW) 2015 will take place in Washington, DC, from May 17 to 19. With more than 400 scientific sessions… 
2013
2013
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1.
Review
2013
Review
2013
Novel immunosuppressive agents in kidney transplantation.
Excellent outcomes have been achieved in the field of renal transplantation. A significant reduction in acute rejection has been… 
2013
2013
THU0131 Tofacitinib (CP-690,550), an oral janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical programme
Background Tofacitinib (CP-690,550) is a novel, oral Janus kinase inhibitor that is being investigated as a targeted… 
Review
2012
Review
2012
JAK inhibitors in psoriasis: a promising new treatment modality.
BACKGROUND Inflammatory cytokines play a crucial role in the pathophysiology of psoriasis. New therapies are targeting Janus… 
Review
2012
Review
2012
Selective JAK1 inhibitor and selective Tyk2 inhibitor patents
Introduction: The JAK family comprises of the four non-receptor tyrosine kinases JAK1, JAK2, JAK3 and Tyk2, which play key, but… 
2010
2010
Population Pharmacokinetic Analysis of Mycophenolic Acid Coadministered With Either Tasocitinib (CP-690,550) or Tacrolimus in Adult Renal Allograft Recipients
Tasocitinib (CP-690,550) is an orally active Janus kinase inhibitor that is in development for prophylaxis of acute rejection… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)